Search results for Ixekizumab

Ixekizumab Biosimilar – Anti-IL17A mAb – Research Grade, ProteoGenix, PX-TA1022

Description of Ixekizumab Biosimilar - Anti-IL17A mAb - Research Grade General information about Ixekizumab Recombinant monoclonal antibody to IL17A. Ixekizumab is a humanized monoclonal antibody used in the treatment of autoimmune diseases. This product is for research use only.

Ixekizumab, Kyinno, KB-1389

Ixekizumab, Abbexa, abx831226

Ixekizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL17A, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146, 158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Ixekizumab ELISA Kit, ProteoGenix, KPTX259

Description of Ixekizumab ELISA Kit The Structure of Ixekizumab ELISA Kit Ixekizumab ELISA Kit is a highly sensitive and specific assay designed for the quantitative measurement of Ixekizumab in various biological samples. Ixekizumab is a humanized monoclonal antibody that specifically targets interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of various autoimmune diseases. The structure of Ixekizumab ELISA Kit is based on the principle of enzyme-linked immunosorbent assay (ELISA), which utilizes the specific binding of antibodies to their target antigen for detection and quantification. The kit consists of pre-coated microplates, which are coated with a monoclonal antibody specific for Ixekizumab. The samples, along with standards and controls, are added to the wells of the microplate and allowed to bind to the immobilized antibody. After washing away any unbound material, a biotinylated detection antibody is added, followed by a streptavidin-horseradish peroxidase (HRP) conjugate. The HRP enzyme catalyzes the conversion of a colorless substrate to a colored product, which is directly proportional to the amount of Ixekizumab present in the sample. The color intensity is measured using a microplate reader at a wavelength of 450 nm. The Activity of Ixekizumab ELISA Kit Ixekizumab ELISA Kit has a high sensitivity and specificity, with a lower limit of detection (LOD) of 0.1 ng/mL and a lower limit of quantification (LOQ) of 0.5 ng/mL. This means that the kit can accurately detect and quantify very low levels of Ixekizumab in biological samples, making it suitable for use in clinical and research settings. The activity of Ixekizumab ELISA Kit is based on the specific binding of the monoclonal antibodies to Ixekizumab. The kit has been validated for use in various biological samples, including serum, plasma, and cell culture supernatants. It has also been shown to have minimal cross-reactivity with other related proteins, ensuring the accuracy and specificity of the results. The Application of Ixekizumab ELISA Kit Ixekizumab ELISA Kit has a wide range of applications, particularly in the field of autoimmune diseases. Ixekizumab is currently approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. The kit can be used to monitor the levels of Ixekizumab in patients undergoing treatment, allowing for personalized dosing and optimization of therapy. In addition, Ixekizumab ELISA Kit can also be used in research studies to investigate the role of IL-17A in various autoimmune diseases. It can be used to measure the levels of Ixekizumab in animal models and in vitro studies, providing valuable insights into the pharmacokinetics and pharmacodynamics of the drug. Furthermore, Ixekizumab ELISA Kit can also be used in the development and production of Ixekizumab biosimilars. Biosimilars are biological products that are highly similar to an approved reference product, and the kit can be used to ensure the quality and consistency of these products. In conclusion, Ixekizumab ELISA Kit is a highly sensitive and specific assay that plays a crucial role in the detection, quantification, and monitoring of Ixekizumab in various biological samples. Its wide range of applications makes it a valuable tool for both clinical and research purposes, contributing to the advancement of autoimmune disease treatment and understanding.

Ixekizumab ELISA Kit, Abbexa, abx395148

Ixekizumab ELISA Kit is a quantitative ELISA kit for detection of Ixekizumab.Ixekizumab is a humanized monoclonal antibody to interleukin-17A which acts as an antiinflammatory agent and is used to treat moderate-to-severe plaque psoriasis. Ixekizumab has not been linked to serum enzyme elevations during therapy or to instances of idiosyncratic acute liver injury.

Ixekizumab Biosimilar - Research Grade, ichor.bio, ICH5165

Detects human IL-17A

Research Grade Ixekizumab (HS856016), abinScience, HS856016